Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar;26(2):183-197.
doi: 10.1007/s40257-025-00917-z. Epub 2025 Feb 7.

Infections in Patients with Atopic Dermatitis and the Influence of Treatment

Affiliations
Review

Infections in Patients with Atopic Dermatitis and the Influence of Treatment

Maddalena Napolitano et al. Am J Clin Dermatol. 2025 Mar.

Abstract

Atopic dermatitis (AD) is a T helper 2-mediated chronic inflammatory skin disease that affects children and adults. Patients with AD are prone to recurrent infections of the skin and other organs, which can severely worsen the disease course. This review summarises the current evidence on the aetiology, pathogenesis, treatment and prevention of infections in patients with AD. PubMed was searched for English-language research articles, systematic reviews, meta-analyses and guidelines published until February 2023 using the key term "atopic dermatitis" and terms relevant to infections. Patients with AD have an increased risk of bacterial, viral and fungal infections of the skin, mainly due to impaired barrier function, altered immune response and frequent scratching. The most common pathogens are Staphylococcus aureus and herpes simplex virus, which can cause impetigo, folliculitis, abscesses, eczema herpeticum and other complications. They also appear to increase susceptibility to systemic infections, including respiratory and urinary tract infections and sepsis. Certain systemic treatments for AD, such as mycophenolate mofetil and Janus kinase inhibitors, increase the risk of viral infections. Prevention and treatment of recurrent infections in patients with AD require a multifaceted approach that includes topical and systemic antimicrobials, skin care and effective control of AD symptoms (to break the itch-scratch cycle). Preventing and limiting the development of infections are important considerations in choosing an AD treatment.

PubMed Disclaimer

Conflict of interest statement

Declarations. Funding: This work, medical writing assistance for the development of this article and the Open Access Fee was funded by Sanofi, Italy. Conflicts of Interest: Maria Esposito has served as a speaker or board member for AbbVie, Almirall, Amgen, Eli Lilly, LEO Pharma, Janssen, Novartis, Pfizer, Sanofi and UCB. Maria Concetta Fargnoli has served as an advisory board member for AbbVie, LEO Pharma, Novartis and Sanofi. Caterina Foti has acted as a speaker, consultant and advisory board member for AbbVie, Amgen, LEO Pharma, Novartis and Sanofi. Giampiero Girolomoni has served on boards for, received research grants from and received personal fees/honoraria for lectures from AbbVie, Almirall, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Galderma, Janssen, LEO Pharma, Merck Serono, Novartis, Pfizer, Pierre Fabre, Samsung Bioepis and Sanofi. Paolo Matruglio and Elena Nicoli are employees of Sanofi and may hold shares and/or stock options in the company. Maddalena Napolitano has acted as speaker, consultant and advisory board member for AbbVie, Amgen, Eli Lilly, LEO Pharma, Pierre Fabre and Sanofi. Paolo Romita declares no potential conflict of interest. Ethics Approval: Not applicable. Consent to Participate: Not applicable. Consent to Publish: Not applicable. Availability of Data and Materials: Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. Code Availability: Not applicable. Author Contributions: M.N., M.E., M.C.F., G.G., P.R. and C.F. contributed to review conception. All authors contributed to the selection of the literature. All authors critically revised the manuscript for intellectual content between drafts and approved the final version for publication.

References

    1. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis Nat Rev Dis Primers. 2018;4(1):1. 10.1038/s41572-018-0001-z. - PubMed
    1. Bekić S, Martinek V, Talapko J, Majnarić L, Vasilj Mihaljević M, Škrlec I. Atopic dermatitis and comorbidity. Healthcare (Basel). 2020;8(2):70. 10.3390/healthcare8020070. - PMC - PubMed
    1. Ali F, Vyas J, Finlay AY. Counting the burden: atopic dermatitis and health-related quality of life. Acta Derm Venereol. 2020;100(12):adv00161. 10.2340/00015555-3511. - PMC - PubMed
    1. Drucker AM. Atopic dermatitis: Burden of illness, quality of life, and associated complications. Allergy Asthma Proc. 2017;38(1):3–8. 10.2500/aap.2017.38.4005. - PubMed
    1. Koszorú K, Borza J, Gulácsi L, Sárdy M. Quality of life in patients with atopic dermatitis. Cutis. 2019;104(3):174–7. - PubMed

MeSH terms

LinkOut - more resources